What Aetna's Alma Rate Cut Means for Psychiatrists

Updated July 9, 2026. Alma told clinicians its Aetna negotiations concluded: the three proposed consolidations were withdrawn, overall rates still fall, and the effective date moved from July 15 to August 15. This analysis originally ran the math on the proposal when it was still coming. The same math now measures what the reversal saved you, and the rest of the post has been updated to match.

On July 9, 2026, Alma told its clinicians that its rate negotiations with Aetna were over. The three consolidations Aetna proposed in May were withdrawn: a 53-plus-minute session (90837) keeps a higher rate than a 45-minute one (90834), a high-complexity visit (99215) keeps a higher rate than a moderate one (99214), and physicians keep a higher rate than NPs. For psychiatrists, those last two would have stacked on every E/M visit and taken roughly $18,000 to $26,000 a year out of a moderately sized Aetna panel. That is what the reversal preserved, and since the surviving cut has no published numbers yet, it is so far the only dollar figure on what clinician pushback won. Here is the exact math, what still changes on August 15, and the three ways to respond.

What Aetna proposed in May, and what survived

Alma notified its clinicians on May 20 that Aetna would flatten three rate differentials for claims billed through the platform, per reporting by Behavioral Health Business and a detailed breakdown at Navigating the Insurance Maze:

None of the three survived the negotiation. In its July 9 email to clinicians, Alma said the 90837 and 90834 rates will not be consolidated, the 99214 and 99215 rates will not be consolidated, and reimbursement will continue to reflect degree type and training.

The rest of the outcome is still a cut. Aetna's final rates reduce overall reimbursement for mental health services billed through Alma: 90837 lands above the withdrawn proposal but below its current level, and less frequently billed codes take reductions. Alma told clinicians it does not consider the outcome a win. The new rates apply to dates of service on or after August 15, 2026; earlier dates of service pay at current rates. Your new rates appear in your Alma account, and as of this writing no rate figures from the final schedule have been published anywhere. Neither the May notice nor the July 9 email addresses the psychotherapy add-on codes you bill with E/M visits (90833, 90836, 90838), so log into your Alma portal and read your updated regional fee schedule line by line rather than assuming either way.

What the withdrawn changes would have cost, in dollars

For a prescriber, the two E/M changes would have compounded: every visit takes the physician-to-NP haircut, and your complex visits additionally lose the 99215 premium. Here is the worked example this post published on July 2, when the changes were still scheduled, for a psychiatrist with 15 weekly Aetna-through-Alma visits. Your fee schedule is the real number; the formula is what transfers.

Assumptions (labeled, so you can swap in your own): 99214 at $130 and 99215 at $180 for an MD, an NP differential of 15 percent (Medicare's is exactly 15 percent; commercial differentials vary), and a 48-week year.

That $21,240 is now the amount the reversal preserved for this example psychiatrist, every year. The formula for your own panel: (your 99215 rate minus your 99214 rate) × weekly 99215 count, plus (your MD rate minus the NP rate) × all weekly E/M visits, × your working weeks. Run it to see what the withdrawal was worth to you, and keep it handy: the same arithmetic prices any future flattening proposal, at Alma or anywhere else, and it prices the surviving cut once you have your new schedule (multiply each code's rate change by your weekly volume of that code). Our calculator runs it with your numbers. For a therapist-side comparison, the historical Alma gap between 90837 and 90834 ran about $15 to $25 per session, which would have been a $4,800 to $14,400 annual loss at 5 to 15 weekly sessions.

If you want a sanity anchor for the complexity differential: on the 2026 Medicare fee schedule, 99215 pays roughly $50 more than 99214 nationally (both numbers are public in CMS's fee schedule lookup). The withdrawn proposal would have taken that $50 to zero on this contract. The reversal kept the gap, on a fee schedule where you still hold no seat at the table.

Why the mechanism still matters

The reversal changes the outcome, and it changes nothing about the mechanism. Three reasons to keep treating this as category news rather than a closed incident.

First, there is precedent. In 2024, contract renewals between Optum/UnitedHealthcare and Alma cut 90837 payouts by about $10 in states like Texas and Florida. Payers have learned that platform fee schedules are the soft target: one negotiation moves rates for tens of thousands of clinicians at once, and no individual provider has appeal rights over the platform's contract. That fact survived this negotiation intact, and the surviving August 15 cut runs through exactly that mechanism.

Second, the consolidation pressure is unchanged. Spring Health acquired Alma on May 1, 2026. Whatever else that means, platform economics under a B2B parent tend to prioritize network scale, which is exactly the negotiating environment where payers extract rate concessions.

Third, and this is the new information from July 9: collective response moved the terms. More than 5,000 clinicians answered Alma's survey within days. The American Psychiatric Association and the American Psychological Association sent Aetna a joint letter urging a pause. Alma credits clinician survey responses and outreach to professional organizations for its case in the negotiation. Nobody outside the negotiating room can prove which pressure moved which term, and Aetna has published nothing about the outcome. But before July 9, the working assumption was that platform repricings simply happen to you. The record now shows one that got partially unwound. It also shows the limit: the pushback moved three terms and did not stop the cut.

Option 1: stay and read your new schedule

The pushback window is over; the negotiation is concluded. What remains in your control is knowing your actual numbers. Pull your current regional fee schedule and the new one from the Alma portal and compare them line by line, including the codes you bill rarely and the psychotherapy add-ons. Alma has said less frequently billed codes take reductions, and no public source will tell you which ones or by how much. Price the difference for your panel with the formula above. If the annual delta is small, staying until your renewal date and deciding with a year of post-cut claims data is a reasonable answer. Do not budget for a further reversal: any future change comes through the next negotiation, not this one.

Do not rage-quit an annual contract on August 14 either. Alma's stated policy is no refunds on annual plans canceled before renewal, so a mid-term exit can cost you the remaining months while also costing you the panel.

Option 2: stay and document defensively

With the 99215 differential preserved, complexity coding keeps paying, which makes documentation the thing to protect. Keep documenting time and complexity rigorously so your 99215s survive audits and downcoding pressure, and so you have a clean record if you later negotiate anywhere else. The honest caveat from the original version of this post still applies: there is no clever code combination that recreates revenue a fee schedule takes away. If your surviving cut turns out to be large, coding will not close the gap; only Option 1's arithmetic or Option 3 will.

Option 3: treat it as your exit ramp

A rate cut you cannot appeal is useful for one thing: it forces the arithmetic you have been putting off. The cut got smaller on July 9, and it is still a cut that was decided in a room you were not in. If you have been running Aetna patients through a platform while thinking about a cash-pay practice, the August 15 repricing is still the natural decision point, and the math is friendlier than most prescribers assume.

Prescribers who have made this exact move report a consistent pattern: when insurance stops working for a panel, roughly 60 percent of established patients choose to stay and pay out of pocket rather than start over with a new prescriber. That is a rule of thumb from real practices; your fees and your local market move it. Applied to an Aetna panel of 20, it means you keep about 12 patients paying your full fee, no platform cut, no payer determining what your time is worth, plus out-of-network superbills that recover part of the cost for patients with PPO plans.

Two mechanics matter if you go this way. First, platform arrangements are built for exactly this move: you can close to new platform patients with a toggle while you build the cash side, which is much cleaner than exiting a direct payer contract. (If you are weighing a move to a different platform instead of to cash, our Headway vs Alma vs Grow Therapy comparison covers clinician-reported rates, referral flow, and exit mechanics for all three.) Second, the transition is an operations problem more than a persuasion problem: patients need clear fees, a superbill for every visit, and a payment experience that does not add friction. This is the part Eureka runs for the practices on it, superbills generated automatically and cards on file charged after each visit, so the switch from copays to direct pay does not become an accounts-receivable job. The full playbook, including how to sequence the patient conversations, is in our guide to transitioning from insurance to cash-pay.

"Read a platform rate cut as contract news. You hold no appeal rights over a fee schedule negotiated between a payer and a platform, so the only rates you actually control are the ones on your own fee sheet," says David Cohen, CPA, JD, who reviewed this article. "If the annual loss clears five figures and your transition plan still works when you cut that 60 percent retention rule of thumb in half, the decision has already been made for you."

The simpler version of the same rule: pull your new schedule, run the formula on the surviving cut, and let the number decide. If the annual loss is a rounding error, stay until renewal. Otherwise set a transition date and use the repricing as the reason you give patients, because it is the true one.

This article describes reimbursement changes as publicly reported and as announced by Alma to its clinicians, and is not billing, legal, or financial advice. Verify your own fee schedules and contract terms, and involve your biller or attorney before appealing claims or exiting a contract.